WO2009125434A3 - Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof - Google Patents

Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof Download PDF

Info

Publication number
WO2009125434A3
WO2009125434A3 PCT/IN2009/000227 IN2009000227W WO2009125434A3 WO 2009125434 A3 WO2009125434 A3 WO 2009125434A3 IN 2009000227 W IN2009000227 W IN 2009000227W WO 2009125434 A3 WO2009125434 A3 WO 2009125434A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical composition
oxime derivatives
same
composition containing
Prior art date
Application number
PCT/IN2009/000227
Other languages
French (fr)
Other versions
WO2009125434A2 (en
Inventor
Harikishore Pingali
Mukul R. Jain
Pandurang Zaware
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2009125434A2 publication Critical patent/WO2009125434A2/en
Publication of WO2009125434A3 publication Critical patent/WO2009125434A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to novel oxime derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
PCT/IN2009/000227 2008-04-07 2009-04-06 Oxime derivatives WO2009125434A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN802/MUM/2008 2008-04-07
IN802MU2008 2008-04-07
IN2693/MUM/2008 2008-12-24
IN2693MU2008 2008-12-24

Publications (2)

Publication Number Publication Date
WO2009125434A2 WO2009125434A2 (en) 2009-10-15
WO2009125434A3 true WO2009125434A3 (en) 2010-04-15

Family

ID=41162348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000227 WO2009125434A2 (en) 2008-04-07 2009-04-06 Oxime derivatives

Country Status (1)

Country Link
WO (1) WO2009125434A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2403120T3 (en) * 2008-12-24 2013-05-14 Cadila Healthcare Limited New oxime derivatives
JP5467151B2 (en) 2009-06-24 2014-04-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel compounds, pharmaceutical compositions and methods relating thereto
AR077214A1 (en) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc NITROGEN HETEROCICLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) * 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN116850181A (en) 2015-01-06 2023-10-10 艾尼纳制药公司 Treatment and S1P 1 Methods of receptor-related disorders
ES2929526T3 (en) 2015-06-22 2022-11-29 Arena Pharm Inc (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl) acid L-arginine crystal salt acetic acid for use in disorders associated with the S1P1 receptor
MA47504A (en) 2017-02-16 2019-12-25 Arena Pharm Inc COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388309A2 (en) * 1989-03-17 1990-09-19 Rhone-Poulenc Sante 1H,3H,7-pyrrolo [1,2-c] thiazolecarboxamides, their preparation and pharmaceutical compositions containing them
WO1994000448A1 (en) * 1992-06-26 1994-01-06 Boehringer Ingelheim Italia S.P.A. Azacyclic and azabicyclic hydroxylamines as muscarinic receptor agonists
WO2005097129A2 (en) * 2004-04-05 2005-10-20 Takeda Pharmaceutical Company Limited 6-azaindole compound
EP1741702A1 (en) * 2004-04-28 2007-01-10 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
WO2007090434A1 (en) * 2005-05-14 2007-08-16 Bayer Cropscience Aktiengesellschaft Substituted aryl oximes
WO2007139150A1 (en) * 2006-05-30 2007-12-06 The University Of Tokushima ANTI-INFLUENZA VIRAL AGENT COMPRISING TNF-α INHIBITOR

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388309A2 (en) * 1989-03-17 1990-09-19 Rhone-Poulenc Sante 1H,3H,7-pyrrolo [1,2-c] thiazolecarboxamides, their preparation and pharmaceutical compositions containing them
WO1994000448A1 (en) * 1992-06-26 1994-01-06 Boehringer Ingelheim Italia S.P.A. Azacyclic and azabicyclic hydroxylamines as muscarinic receptor agonists
WO2005097129A2 (en) * 2004-04-05 2005-10-20 Takeda Pharmaceutical Company Limited 6-azaindole compound
EP1741702A1 (en) * 2004-04-28 2007-01-10 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
WO2007090434A1 (en) * 2005-05-14 2007-08-16 Bayer Cropscience Aktiengesellschaft Substituted aryl oximes
WO2007139150A1 (en) * 2006-05-30 2007-12-06 The University Of Tokushima ANTI-INFLUENZA VIRAL AGENT COMPRISING TNF-α INHIBITOR

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CEREDA, ENZO ET AL: "Preparation of azacyclic and azabicyclic hydroxylamines as muscarinic receptor agonists", XP002559974, retrieved from STN Database accession no. 1995:293707 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KIDO, HIROSHI: "Anti-influenza viral agent comprising TNF-.alpha. inhibitor", XP002559973, retrieved from STN Database accession no. 2007:1396243 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LYLE, ROBERT E. ET AL: "Reactions of 1-methyl-4-halo-4-piperidyl phenyl ketones", XP002559975, retrieved from STN Database accession no. 1960:50427 *
JOURNAL OF ORGANIC CHEMISTRY , 24, 333-8 CODEN: JOCEAH; ISSN: 0022-3263, 1959 *

Also Published As

Publication number Publication date
WO2009125434A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
WO2008035359A3 (en) Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
PH12015501452A1 (en) Novel quinolone derivatives
HK1149258A1 (en) Compounds
MX2010014234A (en) Pyrazole compounds 436.
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2010009163A (en) Heterocyclic urea derivatives and methods of use thereof-211.
WO2008013838A3 (en) Pyridizinone derivatives
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
WO2008010238A3 (en) Antidiabetic azabicyclo [3. 1. 0] hexan compounds
GEP20135806B (en) Lactams as beta secretase inhibitors
WO2008006795A3 (en) Indole compounds
MX2013000474A (en) Novel arylamide derivatives having antiandrogenic properties.
MX2009013501A (en) Piperidine compounds and uses thereof.
MX2010013310A (en) Heterocyclic urea derivatives for the treatment of bacterial infections.
WO2010049449A3 (en) Novel salts of sunitinib
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
MX2013003736A (en) Novel gpr 119 agonists.
UA107473C2 (en) Condensed thiazolo and oksazolopirimidinony
WO2011087712A3 (en) Tricyclic derivatives and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09729734

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09729734

Country of ref document: EP

Kind code of ref document: A2